ODM-201
Phase 2Small molecule
Orion Corporation, Orion PharmaODM-201 is one of 30 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
1
Indications
6
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Acetylsalicylic Acid
BayerPhase 3
GM-CSF
YY-mAbs Therapeutics
Phase 3
Perflutren Lipid Microspheres
SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer3 trials
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02972060·61 enrolled
Maintenance Therapy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ODM-201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details